Nate Taylor is an associate in the New York office of Latham & Watkins and a member of the Litigation & Trial Department.

Mr. Taylor's practice covers a broad range of matters, including contract, fraud, copyright and trademark, trade secret, pharmaceutical antitrust, bankruptcy, employment, and securities disputes. He has successfully represented clients in both state and federal courts, as well as US and international commercial arbitrations, and has won cases at all stages of litigation, including at trial and on appeal.

Mr. Taylor has represented:

  • Cantor Fitzgerald
  • AbbVie Inc.
  • Credit Suisse
  • Teva Pharmaceuticals*
  • Neurocrine Biosciences
  • Tata Consultancy Services
  • UBS
  • Dex Media
  • Upsher-Smith Pharmaceuticals*
  • Lennar Corporation

*Client representation handled prior to joining Latham

Mr. Taylor’s experience includes representing:

  • A national directories publisher, charged with copyright infringement in an action seeking US$750 million in damages as well as a series of follow on lawsuits. Result: Prevailed at trial before the Bankruptcy Court for the District of Delaware and obtained an award of client’s attorneys’ fees of over US$700 thousand.
  • A national construction and real estate company, in a suit alleging fraud and breach of contract by service provider. Result: Complete dismissal of claims in early motion practice.*
  • A global Swiss bank, alleged to have misappropriated software in an arbitration in which Claimant sought over US$1.7 billion. Result: Complete verdict in favor of client after 7-day arbitration hearing and dismissal of all claims.
  • A global private equity investment firm in litigation related to ownership over a national trucking and shipping company. Result: Final award in client’s favor following a 6-day arbitration hearing.
  • A pharmaceutical developer in breach of contract litigation relating to sublicensing rights of a drug discovery tool.
  • A generic pharmaceutical manufacturer in antitrust litigation arising out of patent litigation settlements.*
  • A generic pharmaceutical manufacturer in antitrust litigation claiming alleged price-fixing of generic pharmaceuticals.*

Bar Qualification

  • New York


  • J.D., Cornell Law School, 2014
    cum laude
  • BA, University of Pittsburgh, 2009
    magna cum laude
August 14, 2023 In the News

Del. Justices Uphold Toss of US$875M BGC-Cantor Deal Suit

The Delaware Supreme Court on Thursday upheld a Chancery Court decision to toss a suit challenging the US$875 million acquisition of Berkeley Point Financial LLC by Cantor Fitzgerald LP CEO Howard Lutnick and Lutnick-controlled BGC Partners Inc. in 2017, agreeing it was a fair deal.